The IL-28 genotype: How it will affect the care of patients with hepatitis C virus infection

被引：10

作者：

Pearlman B.L. ^{[1
,2
,3
]}

机构：

[1] Center for Hepatitis C, Atlanta Medical Center, Atlanta, GA 30312

[2] Medical College of Georgia, Augusta, GA

[3] Emory School of Medicine, Atlanta, GA

来源：

Current Gastroenterology Reports | 2011年 / 13卷 / 1期

关键词：

Acute hepatitis C; Chronic hepatitis C; Genome-wide association studies; Hepatitis C; IL-28; polymorphisms; Single-nucleotide polymorphisms; Viral hepatitis;

D O I：

10.1007/s11894-010-0161-9

中图分类号：

学科分类号：

摘要：

The hypothesis that host genetics play an essential role in the ability not only to clear acute hepatitis C infection but also to achieve sustained virologic response (SVR) to interferon (IFN)-based therapy has been proved with the recent discovery of two single-nucleotide polymorphisms on chromosome 19. Variants in the minor allele rs8099917 and the proximate polymorphism rs12979860, 3 kb upstream of the interleukin (IL)-28B gene, which encodes the endogenous antiviral cytokine IFN-λ, are associated with SVR and with natural viral clearance. The disparate frequencies of these alleles in ethnic groups worldwide may well explain differing rates of SVR among them. The test for one of these polymorphisms is now commercially available and can serve as a powerful predictor of a patient's chance of achieving SVR. Perhaps more importantly, the test can help the clinician personally tailor the duration and even the type of therapy that is most appropriate for an individual patient, newly or chronically infected with the hepatitis C virus. © 2010 Springer Science+Business Media, LLC.

引用

页码：78 / 86

页数：8

共 51 条

[1]

Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium, J Viral Hepat, 6, pp. 35-47, (1999)

[2]

Kim W.R., The burden of hepatitis C in the United States, Hepatology, 36, 5 SUPPL. 1, (2002)

[3]

Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M.-H., Albrecht J.K., Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial, Lancet, 358, 9286, pp. 958-965, (2001)

[4]

Fried M.W., Shiffman M.L., Reddy K.R., Et al., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N Engl J Med, 347, pp. 975-982, (2002)

[5]

Conjeevaram H.S., Fried M.W., Jeffers L.J., Terrault N.A., Wiley-Lucas T.E., Afdhal N., Brown R.S., Belle S.H., Hoofnagle J.H., Kleiner D.E., Howell C.D., Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1, Gastroenterology, 131, 2, pp. 470-477, (2006)

[6]

Ge D., Fellay J., Thompson A.J., Et al., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, 461, pp. 399-401, (2009)

[7]

Manolio T.A., Genomewide association studies and assessment of the risk of disease, N Engl J Med, 363, pp. 166-176, (2010)

[8]

Pearson T.A., Manolio T.A., How to interpret a genome-wide association study, JAMA - Journal of the American Medical Association, 299, 11, pp. 1335-1344, (2008)

[9]

Christensen K., Murray J.C., Focus on research: What genome-wide association studies can do for medicine, New England Journal of Medicine, 356, 11, pp. 1094-1097, (2007)

[10]

Tanaka Y., Nishida N., Sugiyama M., Et al., Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C, Nature Genetics, 41, pp. 1105-1109, (2009)

← 1 2 3 4 5 6 →